<SEC-DOCUMENT>0001649094-25-000112.txt : 20251104
<SEC-HEADER>0001649094-25-000112.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104160844
ACCESSION NUMBER:		0001649094-25-000112
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vaxcyte, Inc.
		CENTRAL INDEX KEY:			0001649094
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464233385
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39323
		FILM NUMBER:		251449028

	BUSINESS ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070
		BUSINESS PHONE:		650-837-0111

	MAIL ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SutroVax, Inc.
		DATE OF NAME CHANGE:	20150724
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pcvx-20251104.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1527ac88-e4cf-4f45-b2f7-9017840b2b18,g:ef678305-2538-434a-ac86-05a52b10b852,d:bfc6a8d6504f49c1bb87208c37ce6138-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pcvx-20251104</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001649094</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pcvx-20251104.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-04</xbrli:startDate><xbrli:endDate>2025-11-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibfc6a8d6504f49c1bb87208c37ce6138_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 4, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Vaxcyte, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">01-39323</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-4233385</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">825 Industrial Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">San Carlos</ix:nonNumeric> , <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">California</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">94070</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">837-0111</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">PCVX</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibfc6a8d6504f49c1bb87208c37ce6138_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div id="ibfc6a8d6504f49c1bb87208c37ce6138_10"></div><div style="-sec-extract:summary;margin-top:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pcvx20251104-exx991.htm">Press Release of Vaxcyte, Inc., dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pcvx20251104-exx991.htm">No</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pcvx20251104-exx991.htm">vember 4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="pcvx20251104-exx991.htm">, 2025</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibfc6a8d6504f49c1bb87208c37ce6138_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">VAXCYTE, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">November 4, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Andrew Guggenhime</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Andrew Guggenhime<br/>President and Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pcvx20251104-exx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4089540adce240d0b793365108e25dec_1"></div><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><img alt="img251305552_0.jpg" src="img251305552_0.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data&#59; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to Third and Final Stage</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Establishing Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Aligned with Administration&#8217;s Focus on Strengthening Domestic Biomanufacturing and Representing up to $1 Billion in Manufacturing and Services </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Appoints Mike Mullette as Chief Commercial Officer as it Advances VAX-31 to Phase 3 and Potential Commercialization </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Remains Focused on Disciplined Capital Allocation and Prioritizing Resources for PCV Programs with Approximately $2.7 Billion in Cash, Cash Equivalents and Investments as of September&#160;30, 2025,Expected to Fund Current Operating Plan into Mid-2028</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SAN CARLOS, Calif., November 4, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#8211; Vaxcyte, Inc. (Nasdaq&#58; PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update, including the final data from the VAX-24 infant Phase 2 dose-finding study. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;We remain laser-focused on advancing the development of VAX-31, the broadest-spectrum pneumococcal conjugate vaccine (PCV) in the clinic, given its potential to substantially broaden protection against both currently circulating and historically prevalent serotypes compared to currently available PCVs,&#8221; said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. &#8220;For the adult indication, we expect to initiate the VAX-31 pivotal, non-inferiority study in December, with additional Phase 3 study initiations in 2026. For the infant indication, the final data from our VAX-24 infant Phase 2 dose-finding study are consistent with the previously reported positive interim data and show that VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed. These results further validate our rationale for exploring higher doses in the ongoing VAX-31 infant Phase 2 dose-finding study. Together, the growing body of data from both the adult and infant programs reinforces our conviction that VAX-31 has a potential best-in-class profile.&#8221;   </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;We continue to take a disciplined approach to capital allocation, ending the third quarter with $2.7 billion in cash, cash equivalents and investments,&#8221; said Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. &#8220;With this strong financial position, we are advancing both the VAX-31 adult Phase 3 program and the infant Phase 2 study while investing in activities to help ensure commercial readiness. As part of that effort, our recent agreement to significantly expand our fill-finish manufacturing capacity in North Carolina further strengthens our supply chain and underscores our commitment to American biomanufacturing and innovation &#8212; all in service of our mission to deliver vaccines that protect against serious infectious diseases.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Key Third Quarter and Recent Highlights </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">PCV Program Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Final VAX-24 Infant Phase 2 Dose-Finding Study Data Consistent with Previously Reported Positive Interim Data&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> In March 2025, the Company announced topline, interim data from the VAX-24 infant Phase 2 study, a randomized, observer-blind, dose-finding two-stage clinical study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy infants that enrolled 803 participants.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Today, the Company shared the final safety, tolerability, and immunogenicity results from this study that are consistent with the previously reported positive interim data and show that VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed. The totality of data from this study affirms the Company&#8217;s strategy to include the higher doses that are being evaluated in the ongoing VAX-31 infant Phase 2 dose-finding study. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The final data analysis includes full 6-month safety results and complete post-dose 3 (primary immunization series) and post-dose 4 (booster dose) immunoglobulin G (IgG) and opsonophagocytic assay (OPA) results. The key immunogenicity endpoints include an assessment of immune responses for each of the VAX-24 dose levels (Low, Mid, Mixed) in comparison with Prevnar 20 (PCV20) for the 20 common and 4 unique serotypes in VAX-24. At 1-month post-dose 3 and post-dose 4, immune responses were assessed based on serotype-specific IgG seroconversion rates (IgG threshold value of &#8805;0.35mcg&#47;mL). IgG Geometric Mean Ratios (GMRs) were also assessed at 1-month post-dose 3 and post-dose 4, along with other key immunogenicity endpoints, including OPA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In this study, VAX-24 was well-tolerated and demonstrated a safety profile similar to PCV20 across all doses studied. Frequently reported local and systemic reactions were generally mild-to-moderate, resolving within several days of vaccination, with no meaningful differences observed across the cohorts. No serious adverse events were considered to be related to study vaccines. Post-dose 3 and post-dose 4, all VAX-24 doses evaluated demonstrated robust IgG and OPA immunogenicity responses. </font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Post-dose 3, all VAX-24 doses met target precedent Phase 2 non-inferiority (NI) criteria on relative seroconversion rates</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> for the highest circulating serotypes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> contained in VAX-24. The Low and Mid doses met the NI criteria for 20 of 24 serotypes overall and the Mixed dose met such criteria for 19 of 24 serotypes. The Mid and Mixed doses met the target Phase 2 IgG GMR point estimate of &#62;0.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> for 21 of 24 serotypes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Post-dose 4, all VAX-24 doses met the Company&#8217;s target Phase 2 IgG GMR point estimate of &#62;0.6 for the three highest circulating serotypes contained in VAX-24. The Mixed dose met this target for 19 of 24 serotypes overall and the Mid dose met this target for 18 of 24 serotypes. Post-dose 4, VAX-24 elicited robust memory responses across all doses for all serotypes.    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Additionally, the four incremental serotypes unique to VAX-24 that provide expanded serotype coverage relative to PCV20 elicited robust immune responses and met all target criteria across all endpoints at all doses evaluated.    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Additional information about the study can be found at www.clinicaltrials.gov under the identifier NCT05844423.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Advanced VAX-31 Infant Phase 2 Dose-Finding Study to Third and Final Stage&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In September 2025, the Company announced that the modified VAX-31 infant Phase 2 randomized, dose-finding study had progressed to the third and final stage. VAX-31 is designed to substantially expand coverage in the pediatric population relative to today&#8217;s standard-of-care, PCV20, by adding 11 incremental serotypes with the potential to increase protection against invasive pneumococcal disease (IPD) from approximately 69% to approximately 92% of disease circulating in children under five years of age in the U.S. This study is evaluating the safety, tolerability and immunogenicity of VAX-31 compared to PCV20 in approximately 900 healthy infants. The study advanced to the final stage following protocol modifications to add a new dose arm to evaluate the VAX-31 Optimized Dose (majority of serotypes dosed at 4.4mcg and the balance dosed at 3.3mcg) and to discontinue enrollment in the Low Dose arm. The Middle and High Dose arms are continuing as planned. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Additional information about the study can be found at www.clinicaltrials.gov under the identifier NCT06720038. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">U.S. Commercial Manufacturing Expansion </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Establishing Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> In September 2025, the Company announced a new agreement with Thermo Fisher Scientific Inc. to provide custom commercial fill-finish capacity for the Company&#8217;s broad-spectrum PCVs at Thermo Fisher&#8217;s Greenville, North Carolina facility. This initiative, which includes both manufacturing and related services, represents a long-term U.S. commercial manufacturing commitment of up to $1 billion. Establishing this capacity strengthens the Company&#8217;s supply chain, </font></div><div style="border-bottom:0.5pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Lower limit of the 95% confidence interval for the difference in the proportion of participants achieving the pre-defined seroconversion rate (IgG concentration &#8805;0.35 mcg&#47;mL) is &#62; -15% for each ST (https&#58;&#47;&#47;pmc.ncbi.nlm.nih.gov&#47;articles&#47;PMC7360095&#47;). Larger Phase 3 registration studies have required that lower limit of the 95% confidence interval for the difference in the proportion of participants achieving the pre-defined seroconversion rate (IgG concentration &#8805;0.35 mcg&#47;mL) be &#62; -10% for each ST.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Percentage of IPD caused in individuals &#60;5 yrs of age in the U.S. in 2023 based on ABC surveillance data (https&#58;&#47;&#47;data.cdc.gov&#47;Public-Health-Surveillance&#47;1998-2023-Serotype-Data-for-Invasive-Pneumococcal-&#47;qvzb-qs6p&#47;about_data).</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Target point estimate of 0.6 is based on the Company&#8217;s statistical analysis of precedent Phase 2 and Phase 3 studies.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">supports future commercial readiness and aligns with the Administration&#8217;s focus on expanding domestic biomanufacturing infrastructure.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Executive Leadership Team Appointment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company Appointed Mike Mullette as Chief Commercial Officer to Lead Commercialization Strategy and Execution&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> In October 2025, Mike Mullette joined Vaxcyte as Chief Commercial Officer, bringing more than 20 years of global experience in vaccines and biopharmaceuticals, including senior leadership roles at Moderna, Sanofi Pasteur and Lykos Therapeutics. As part of the Company&#8217;s strategy to prepare for future commercialization of its PCV programs, Mr. Mullette will lead the continued development and execution of global commercialization, including pre-launch planning and cross-functional readiness. He brings extensive launch leadership, having led Moderna&#8217;s first ever commercial organization in North America during the COVID-19 pandemic and launched multiple vaccines at Sanofi Pasteur across the U.S., France, Japan, Australia and Canada. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Anticipated Key Milestones</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key upcoming milestones&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">PVC Franchise Adult Indication</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">VAX-31</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">Initiate the VAX-31 Phase 3 pivotal, non-inferiority study in December 2025 and announce topline safety, tolerability and immunogenicity data in 2026.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">Initiate remaining Phase 3 studies in 2026 and announce data from these studies in 2027.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">PCV Franchise Infant Indication</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">VAX-31</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">Announce topline safety, tolerability and immunogenicity data for the VAX-31 infant Phase 2 randomized, dose-finding study from both the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Upcoming Investor Conferences</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences. A live webcast of the fireside chats will be accessible through the Investors &#38; Media section of the Company's website at http&#58;&#47;&#47;investors.vaxcyte.com for approximately 30 days following each conference. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:12.03pt">Guggenheim Healthcare Innovation Conference, November 10-12&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Fireside chat will take place live on Tuesday, November 11, at 2&#58;30 p.m. ET &#47; 11&#58;30 a.m. PT.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:12.03pt">Jefferies London Healthcare Conference, November 17-20&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Fireside chat will take place live on Wednesday, November 19, at 2&#58;30 p.m. GMT &#47; 9&#58;30 a.m. ET.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:12.03pt">Evercore ISI HealthCONx Conference, December 2-4&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Fireside chat will take place live on Tuesday, December 2, at 1&#58;20 p.m. ET &#47; 10&#58;20 a.m. PT. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Quarter 2025 Financial Results </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:12.03pt">Cash Position&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Cash, cash equivalents and investments were $2,670.6 million as of September&#160;30, 2025, compared to $3,134.7 million as of December&#160;31, 2024. <br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:12.03pt">Research &#38; Development (R&#38;D) Expenses&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">R&#38;D expenses were $209.9 million for the three months ended September&#160;30, 2025 as compared to $116.9 million for the same period in 2024. The increase was due primarily to development and manufacturing activities in connection with the adult and infant PCV programs, including support for potential future commercial launches, as well as higher personnel expenses related to the growth in the number of R&#38;D employees.      <br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:12.03pt">General &#38; Administrative (G&#38;A) Expenses&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">G&#38;A expenses were $32.4 million for the three months ended September&#160;30, 2025 as compared to $23.0 million for the same period in 2024. The increase was due primarily to higher personnel expenses related to the growth in the number of G&#38;A employees.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%"><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:12.03pt">Net Loss&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For the three months ended September&#160;30, 2025, net loss was $212.8 million, compared to $103.1 million for the same period in 2024.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:12.03pt">Commercial Manufacturing Suite&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> In the third quarter of 2025, Vaxcyte incurred an additional $23.0 million in capital and facility buildout expenditures related to the ongoing construction of the dedicated manufacturing suite at Lonza intended to support the potential global commercialization of the Company&#8217;s PCV programs. As of September&#160;30, 2025, Vaxcyte had incurred $313.7 million in total capital and facility buildout expenditures that were reflected on the Company&#8217;s balance sheet as of that date. Vaxcyte continues to expect the buildout to be completed by early 2026, with total costs expected to be up to $350 million.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About Vaxcyte </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF&#174;, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company&#8217;s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte&#8217;s pipeline also includes VAX-A1, a prophylactic vaccine </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Forward-Looking Statements</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte&#8217;s carrier-sparing platform and PCV candidates, including breadth of coverage, the ability to deliver potentially best-in-class PCVs, improve upon the standard-of-care and substantially broaden protection against both currently circulating and historically prevalent serotypes&#59; the process and timing of anticipated future development of Vaxcyte's vaccine candidates, including the timing and availability of data for the VAX-31 infant Phase 2 study, and the initiation of VAX-31 adult Phase 3 studies and the timing of such studies and their data readouts&#59; the future commercialization of Vaxcyte&#8217;s PCV programs&#59; Vaxcyte&#8217;s cash runway&#59; and other statements that are not historical fact. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;on track,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte&#8217;s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte&#8217;s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes&#59; the success, cost and timing of all development activities and clinical trials&#59; and sufficiency of cash and other funding to support Vaxcyte&#8217;s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte&#8217;s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management&#8217;s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Readers should not rely upon the information in this press release as current or accurate after its publication date.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"># # #</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Patrick Ryan, Executive Director, Corporate Affairs </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Vaxcyte, Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">415-606-5135 </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">media&#64;vaxcyte.com </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Jeff Macdonald, Executive Director, Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Vaxcyte, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">917-371-094</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">investors&#64;vaxcyte.com</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><div id="i4089540adce240d0b793365108e25dec_4"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaxcyte, Inc.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</font></div><div style="margin-bottom:8pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:4.37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">116,936&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">552,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">343,030&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:4.37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,447&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,988&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,146&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">242,380&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139,924&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">649,392&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">407,377&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(242,380)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(139,924)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(649,392)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(407,377)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,057&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93,267&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,536&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">291&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,743&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,004&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,550&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,800&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">129,271&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,530&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(212,830)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(103,124)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(520,121)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(326,847)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.56)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.83)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.83)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.78)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,196,512</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">123,693,461</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,975,586</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,596,424</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</font></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.57pt">Amounts include stock-based compensation expense as follows&#58;</font></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,383&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,499&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,533&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,923&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,405&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,349&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,919&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total stock-based compensation expense</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,306&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,265&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,848&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,452&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i4089540adce240d0b793365108e25dec_7"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaxcyte, Inc.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Consolidated Balance Sheet Data</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.481%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30,<br>2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash, cash equivalents and investments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,670,576&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,134,718&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,171,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,511,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,892,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,305,819&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pcvx-20251104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1527ac88-e4cf-4f45-b2f7-9017840b2b18,g:ef678305-2538-434a-ac86-05a52b10b852-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pcvx="http://www.vaxcyte.com/20251104" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vaxcyte.com/20251104">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20251104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20251104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vaxcyte.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>pcvx-20251104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1527ac88-e4cf-4f45-b2f7-9017840b2b18,g:ef678305-2538-434a-ac86-05a52b10b852-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_0c4e1fc8-503d-4103-9af5-229cfe19ff30_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1eb9a7c2-84f3-4656-8de8-11466bb02e89_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f99b1c75-a8a8-4936-8ce9-a7005c2d3663_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b00dc0fd-a39d-4317-b472-7992e94ac18c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f6874219-59f9-4551-832f-52064d5652e2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c46ae41f-98d7-4d8b-9e06-60537ce7d607_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ba1dc710-b96a-497a-9433-b76757adf7f6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_81665587-88a9-44e8-93fa-33a0011301ea_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b91bbb8d-50d1-42df-a099-eb085f75b1a2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_af6a88ef-dbb8-47d1-87a8-f445595be05a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c14ddaab-d6e5-451e-b292-4211782028b5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_03c8a779-bebb-457a-a527-cb62f304d4dd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3d72496b-7875-4ea9-809b-0f4634570a97_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ba709dc4-9f9b-44de-b4d0-892d8661fa76_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_67d63fe9-5cfe-477d-b86a-3ef5d6ecd33b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50f5eab2-4938-49fc-af9f-e7f67e499d78_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c5241044-78f0-425b-bfbc-5c1f8cd30f60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ea146724-db0d-4959-b573-17fcdc49b2ff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1f9b1bbd-40d3-41b0-abec-266741d4bd24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_48094954-b145-49aa-b7bb-ca2c4f075d88_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_8ec54cfd-ef13-4af4-b051-e3dfa71e3899_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3c4ec6b9-1b53-4649-9518-21908e86d77e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b19e70c5-8867-4eab-855d-399d8706cf9c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>pcvx-20251104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1527ac88-e4cf-4f45-b2f7-9017840b2b18,g:ef678305-2538-434a-ac86-05a52b10b852-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vaxcyte.com/role/Cover" xlink:type="simple" xlink:href="pcvx-20251104.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ff26171b-748d-4f4c-b7df-106ba546a1f8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_DocumentType_ff26171b-748d-4f4c-b7df-106ba546a1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f00b8986-b488-4f8d-a180-0ecd33c7084d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_DocumentPeriodEndDate_f00b8986-b488-4f8d-a180-0ecd33c7084d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_646c000c-5eed-4abc-a7f5-c1058949ae0e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityRegistrantName_646c000c-5eed-4abc-a7f5-c1058949ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5fe35162-cf97-48df-ad61-665579b3541b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5fe35162-cf97-48df-ad61-665579b3541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_aa781999-6d7a-439e-8b5b-2dad0a577714" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityFileNumber_aa781999-6d7a-439e-8b5b-2dad0a577714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0122d854-db01-4a89-a697-962298eacab4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityTaxIdentificationNumber_0122d854-db01-4a89-a697-962298eacab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_34d49daa-25db-4a95-af42-c71327614341" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityAddressAddressLine1_34d49daa-25db-4a95-af42-c71327614341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_238c8492-e4b5-494d-8e56-f21b80620c46" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityAddressAddressLine2_238c8492-e4b5-494d-8e56-f21b80620c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eadd3d3b-45e6-4c34-a910-7a15cf60d1c3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityAddressCityOrTown_eadd3d3b-45e6-4c34-a910-7a15cf60d1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e6610726-2c71-487d-8f18-3a3b6555ee8a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityAddressStateOrProvince_e6610726-2c71-487d-8f18-3a3b6555ee8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_98fba0f9-a5bb-4100-9cb0-94d9e7c3bfdf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityAddressPostalZipCode_98fba0f9-a5bb-4100-9cb0-94d9e7c3bfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_cb3be6c3-ecf1-4d4a-b246-ae66ef90b4ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_CityAreaCode_cb3be6c3-ecf1-4d4a-b246-ae66ef90b4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_263798d6-8b87-44be-8867-85e41b4aac9e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_LocalPhoneNumber_263798d6-8b87-44be-8867-85e41b4aac9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_dc607e10-edee-49e8-a973-cc3a962bb853" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_WrittenCommunications_dc607e10-edee-49e8-a973-cc3a962bb853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_77c2ad8e-005d-46fa-a2cf-ab3e0c137c99" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_SolicitingMaterial_77c2ad8e-005d-46fa-a2cf-ab3e0c137c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_14e39c69-f678-4332-9faa-75e2ddd99571" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_PreCommencementTenderOffer_14e39c69-f678-4332-9faa-75e2ddd99571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_1db80c23-1b34-403b-afa3-46b3270622ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_1db80c23-1b34-403b-afa3-46b3270622ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a4e69e1b-6185-4e00-a3cc-055b210fdc34" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_Security12bTitle_a4e69e1b-6185-4e00-a3cc-055b210fdc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3d187cef-503b-4af4-a402-5180d1caeb83" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_TradingSymbol_3d187cef-503b-4af4-a402-5180d1caeb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3a222b3a-3363-4565-96fb-a6f5b710a7b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_SecurityExchangeName_3a222b3a-3363-4565-96fb-a6f5b710a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_068550a2-4229-4f30-b7c8-fd53e099a388" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityEmergingGrowthCompany_068550a2-4229-4f30-b7c8-fd53e099a388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d5a69fc4-4762-42a5-9a4d-4ff852027318" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_EntityCentralIndexKey_d5a69fc4-4762-42a5-9a4d-4ff852027318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fdbfdc11-630e-4bf3-b389-90340aa05dcb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c98eff3f-ec19-4a6c-a721-af46654907f7" xlink:to="loc_dei_AmendmentFlag_fdbfdc11-630e-4bf3-b389-90340aa05dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img251305552_0.jpg
<TEXT>
begin 644 img251305552_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" ?D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-#T]WL;9G:VC+,T*DD[1R>*N_P!DZ;_T#[3_ +\K_A1S!8\4KK?A[_R'Y_\
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M%%044-<_Y &I?]>LO_H)KQ>O:-<_Y &I?]>LO_H)KQ>KB3(]DT6>$:#IP,J
MBUBR"P_NBK_VB#_GM'_WT*\,HHY0YCW/[1!_SVC_ .^A1]H@_P">T?\ WT*\
M,HHY0YCW8$$ @Y!Z$4M4-#_Y &F_]>L7_H(J_4%!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!1;1=*9BS:99DDY),"\_I4EOIMA:2>9;65M#)C&Z
M.)5./J!5JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV,0VLL;2?."9 G.&/.!D@<?_ %JJ75X+Z:._N5+VH?;I]D.MP_3>P]/KT_\
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MWCB66VTR>98I+EQL,BGKMST7'.3U_ UIS:[IUA;"&RQ=-%'E8K<[@J@=6;H
M.YIK$0N]=%_6@_:QNS:HKB],;6-6:XU&XO'L[,J0SKD?(.H0=O\ >Z_K4&GW
MM]_8=ZFG&3;ODGDN96),:XX7..7.,Y'3([GC-8Q:/E=G<CVZ['=T5SFDZEIV
MD^'[99KU))"N\HAW.6;)QM'Y50N]8^WP/=7$TD=H0?L]C ^))@,@LY'(7AL_
M3VYMXJ*BGU[%.JDO,[*BL#P]:VNDZ.+R9XH3= 2.Q?"J#RJC/H#]<YY-,O\
M6)KFTEFMO,MM.1<R797#O[1@^N0-Q]?:J]NE!2EOV'[3W;LZ*FI(DJ!XW5T8
M9#*<@UPDFHZA<>%642R&&,8FG=B6E9FX0$\X /)]L=.O5Q26&@Z5!#-<QQQQ
MIP2>7/<@<DY)SQZU-/$*;VLK7%&JI>A9O[V/3[&:[E^Y&N<>I[#\3@5Q=A=6
MVHZAY%[=;1/*KSJ 3Y\F<+&",X1>.I^G;":YJ4^NRPQQP/#8I.L1:4[<R'UZ
MXP,^N._7%:%K8:;H\\4U]/#-=Q\0VELN[:WL/O,Q[%O;T&.6I5=:I[OPKO\
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M*GV<.R)Y(]C*M_#>D6THDCLD+#IO8N/R)(JUJ.FVVJ6Z072L8U</A6QDC_\
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ML\'VC[1Y,?G8V^9M&['IFI***+6 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vaxcyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">01-39323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4233385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">825 Industrial Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Carlos<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-0111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001649094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pcvx-20251104.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="pcvx-20251104.htm">pcvx-20251104.htm</File>
    <File>pcvx-20251104.xsd</File>
    <File>pcvx-20251104_lab.xml</File>
    <File>pcvx-20251104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pcvx-20251104.htm": {
   "nsprefix": "pcvx",
   "nsuri": "http://www.vaxcyte.com/20251104",
   "dts": {
    "inline": {
     "local": [
      "pcvx-20251104.htm"
     ]
    },
    "schema": {
     "local": [
      "pcvx-20251104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pcvx-20251104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcvx-20251104_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.vaxcyte.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcvx-20251104.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcvx-20251104.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vaxcyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001649094-25-000112-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001649094-25-000112-xbrl.zip
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ME>MI")\YZ=-9*6:3N"*I4FG]\,,/IS&//=8*G=N)@JO6=<TZK:0O3ROIT(/
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MTAYQ-ES8)DGOLA&'%Q!4TC^-(_^>3NO_4$L#!!0    ( !6!9%M!7C\'7P(
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M>-+V^BX4-BOJNLCWTQ?K9[+E361/7_P?4$L#!!0    ( !6!9%L&U83ETP8
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MRR)>YF-@=)"-))^X1]"8Q%Q&*%#O@HDM !(NJ4&063A!?'B,@8^Q#'Q4/6I
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MQ\6+EC5DM*N&.6@X93D%^-HL"U(Q#WB).M(UU!8Y8VC8&>Q5C(:7P?X'/&F
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M!U!+ 0(4 Q0    ( !6!9%OD%<P<C@\  %YJ   1              "  0
M  !P8W9X+3(P,C4Q,3 T+FAT;5!+ 0(4 Q0    ( !6!9%M!7C\'7P(  /8&
M   1              "  ;T/  !P8W9X+3(P,C4Q,3 T+GAS9%!+ 0(4 Q0
M   ( !6!9%LF@ZY@00H  !18   5              "  4L2  !P8W9X+3(P
M,C4Q,3 T7VQA8BYX;6Q02P$"% ,4    "  5@61;!M6$Y=,&  #V,@  %0
M            @ &_'   <&-V>"TR,#(U,3$P-%]P<F4N>&UL4$L! A0#%
M  @ %8%D6YYF,,F/)@  -48! !<              ( !Q2,  '!C=G@R,#(U
E,3$P-"UE>'@Y.3$N:'1M4$L%!@     %  4 20$  (E*      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>pcvx-20251104_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pcvx-20251104.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001649094</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Vaxcyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">01-39323</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-4233385</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">825 Industrial Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">San Carlos</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">94070</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">837-0111</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">PCVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
